Imagion Biosystems Limited (Imagion, ASX:IBX) has entered into a Service Agreement with StarFish Medical (“StarFish”), Canada’s largest medical device design, development and contract manufacturing company, to assist in the design and development of the MagSense instrument platform for clinical applications.
View the ASX announcement, “Imagion Biosystems Initiates MagSense Instrument Development.”
The Unanswered Question in Prostate Cancer Diagnosis
September 24, 2026
Separating lethal disease from indolent disease remains the persistent difficulty, and molecular MRI may offer a way to see the difference. Prostate cancer is the